Mitochondrial metabolism sustains CD8+ T cell migration for an efficient infiltration into solid tumors
(1) Simula L (2) Fumagalli M (3) Vimeux L (4) Rajnpreht I (5) Icard P (6) Birsen G (7) An D (8) Pendino F (9) Rouault A (10) Bercovici N (11) Damotte D (12) Lupo-Mansuet A (13) Alifano M (14) Alves-Guerra MC (15) Donnadieu E
(1) Simula L (2) Fumagalli M (3) Vimeux L (4) Rajnpreht I (5) Icard P (6) Birsen G (7) An D (8) Pendino F (9) Rouault A (10) Bercovici N (11) Damotte D (12) Lupo-Mansuet A (13) Alifano M (14) Alves-Guerra MC (15) Donnadieu E
The ability of CD8(+) T cells to infiltrate solid tumors and reach cancer cells is associated with improved patient survival and responses to immunotherapy. Thus, identifying the factors controlling T cell migration in tumors is critical, so that strategies to intervene on these targets can be developed. Although interstitial motility is a highly energy-demanding process, the metabolic requirements of CD8(+) T cells migrating in a 3D environment remain unclear. Here, we demonstrate that the tricarboxylic acid (TCA) cycle is the main metabolic pathway sustaining human CD8(+) T cell motility in 3D collagen gels and tumor slices while glycolysis plays a more minor role. Using pharmacological and genetic approaches, we report that CD8(+) T cell migration depends on the mitochondrial oxidation of glucose and glutamine, but not fatty acids, and both ATP and ROS produced by mitochondria are required for T cells to migrate. Pharmacological interventions to increase mitochondrial activity improve CD8(+) T cell intratumoral migration and CAR T cell recruitment into tumor islets leading to better control of tumor growth in human xenograft models. Our study highlights the rationale of targeting mitochondrial metabolism to enhance the migration and antitumor efficacy of CAR T cells in treating solid tumors.
Author Info:
(1) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. luca.simula@inserm.fr. (2) Institut Cochin
, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (3) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (4) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (5) Universit de Normandie, UNICAEN, Inserm U1086 Interdisciplinary Research Unit for Cancer Prevention and Treatment, Caen, France. Thoracic Surgery Department, Cochin Hospital, APHP-Centre, Universit Paris-Cit, Paris, France. (6) Department of Pneumology, Thoracic Oncology Unit, Cochin Hospital, APHP-Centre, Universit Paris-Cit, 75014, Paris, France. (7) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (8) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (9) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (10) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. (11) Department of Pathology, Cochin Hospital, APHP-Centre, Universit Paris-Cit, 75014, Paris, France. (12) Department of Pathology, Cochin Hospital, APHP-Centre, Universit Paris-Cit, 75014, Paris, France. (13) Thoracic Surgery Department, Cochin Hospital, APHP-Centre, Universit Paris-Cit, Paris, France. Inserm U1138, Integrative Cancer Immunology Unit, 75006, Paris, France. (14) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Paris, 75014, France. (15) Institut Cochin, Inserm U1016, CNRS UMR8104, Universit Paris-Cit, Equipe labellise "Ligue contre le Cancer", Paris, 75014, France. emmanuel.donnadieu@inserm.fr.
Citation: Nat Commun 2024 Mar 11 15:2203 Epub03/11/2024
